In contrast, SLC38A2 was mainly associated with epithelial‐mesenchymal transition (EMT), angiogenesis and inflammation‐related pathways (e.g., allograft rejection, IL2‐STAT5 signalling, IL6‐JAK‐STAT3 signalling, inflammatory response and interferon alpha/gamma response), implying the potential involvement of SLC38A2 in regulating the tumour immune microenvironment. This evidence concerns the gene IL6 and neoplasm.